 Shares of Italian diagnostic specialist DiaSorin surged 7 on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. for around 1.8 billion. DiaSorin will pay 37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. 